Phase III SYNERGY Trial: Disappointing Results in Metastatic CRPC
Teva Pharmaceutical Industries Ltd. and OncoGenex Pharmaceuticals, Inc. today announced results from the Phase III SYNERGY trial, a randomized, open-label, two-arm study comparing the combination of custirsen and standard first-line docetaxel/prednisone therapy to docetaxel/prednisone alone in men with metastatic castrate-resistant prostate cancer (CRPC)
ASTRO's New Guidelines on Post-operative Radiation Therapy for Endometrial Cancer
The American Society for Radiation Oncology (ASTRO) has issued a new guideline, The Role of Postoperative Radiation Therapy for Endometrial Cancer: An ASTRO Evidence-Based Guideline, that details the use of adjuvant radiation therapy in the treatment of endometrial cancer. The guideline's executive summary is published in the May-June 2014 issue of Practical Radiation Oncology (PRO), the official clinical practice journal of ASTRO. The full-length guideline is available as an open-access article online.
Promising AML Treatment to Initiate Phase III Trial at Moffitt
Moffitt Cancer Center researchers say clinical trials for a new experimental drug to treat acute myeloid leukemia (AML) are very promising. Patients treated with CPX-351, a combination of the chemotherapeutic drugs cytarabine and daunorubicin, are showing better responses than patients treated with the standard drug formulation.
First Human HPV DNA Test for Cervical Cancer Screening Receives FDA Nod
The U.S. Food and Drug Administration today approved the first FDA-approved HPV DNA test for women 25 and older that can be used alone to help a health care professional assess the need for a woman to undergo additional diagnostic testing for cervical cancer. The test also can provide information about the patient's risk for developing cervical cancer in the future.
Physician Payment Data is Where the Action Is
Look beyond the EHR incentive program. A national effort to turn CMS's recent release of Medicare physician payment data into useful, actionable data visualizations is the hottest HIT challenge right now.
Meet GenBank, the Tool that lets Scientists Unlock the Secrets Within the Data
What is the most important research tool in biology paid for by taxpayers that they don't know exists? It might be GenBank, the open-access database maintained by the National Institutes of Health, which allows scientists to dramatically reduce the time it takes to find druggable targets and identify genes in the evolution of personalized medicine.
FDA Advisory Committee Votes Against Moxduo Approval
- QRxPharma (ASX: QRX and OTCQX: QRXPY)
announced today that the United States Food and Drug Administration (FDA) Anesthetic and
Analgesic Drug Products Advisory Committee has voted to recommend against approval of Moxduo,
an immediate release Dual Opioid® for the treatment of moderate to severe acute pain. The Advisory
Committee found the Company did not provide sufficient evidence to warrant approval of Moxduo at